(Q47976309)

7 February 2018

title

Four year immunogenicity of the RTS,S/AS02(A) malaria vaccine in Mozambican children during a phase IIb trial. (English)

1 reference

7 February 2018

0 references

1 reference

7

1 reference

7 February 2018

Jahit Sacarlal

Jahit Sacarlal

3

0 references

Pedro L. Alonso

20

Pedro L Alonso

1 reference

7 February 2018

18

W Ripley Ballou

1 reference

7 February 2018

John J Aponte

4

John J Aponte

1 reference

7 February 2018

Johan Vekemans

16

Johan Vekemans

1 reference

7 February 2018

Marc Lievens

15

Marc Lievens

1 reference

7 February 2018

Marie-Claude Dubois

13

Marie-Claude Dubois

1 reference

7 February 2018

Eusebio Macete

10

Eusebio Macete

1 reference

7 February 2018

Inacio Mandomando

5

Inácio Mandomando

1 reference

7 February 2018

Pedro Aide

1

Pedro Aide

1 reference

7 February 2018

Montse Renom

8

Montse Renom

1 reference

7 February 2018

Amanda J Leach

12

Amanda Leach

1 reference

7 February 2018

Carlota Dobaño

2

Carlota Dobaño

1 reference

7 February 2018

Christian Loucq

17

Christian Loucq

1 reference

7 February 2018

Laura Puyol

9

Laura Puyol

1 reference

7 February 2018

author name string

Caterina Guinovart

6

1 reference

7 February 2018

Esperanza Herreros

11

1 reference

7 February 2018

Marie-Ange Demoitie

14

1 reference

7 February 2018

Joe Cohen

19

1 reference

7 February 2018

language of work or name

English

0 references

publication date

7 April 2011

1 reference

7 February 2018

published in

Vaccine

1 reference

7 February 2018

volume

29

1 reference

7 February 2018

issue

35

1 reference

7 February 2018

page(s)

6059-6067

1 reference

7 February 2018

Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.041

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.041

Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.041

Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.041

Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.041

Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.041

Plasmodium falciparum-specific cellular immune responses after immunization with the RTS,S/AS02D candidate malaria vaccine in infants living in an area of high endemicity in Mozambique

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.041

Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.041

Long-term safety and efficacy of the RTS,S/AS02A malaria vaccine in Mozambican children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.041

Levels and trends of demographic indices in southern rural Mozambique: evidence from demographic surveillance in Manhiça district

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.041

Safety of the RTS,S/AS02A malaria vaccine in Mozambican children during a Phase IIb trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.041

Development and technical and clinical validation of a quantitative enzyme-linked immunosorbent assay for the detection of human antibodies to hepatitis B surface antigen in recipients of recombinant hepatitis B virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.041

A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine candidates in children in Gabon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.041

Randomized controlled trial of RTS,S/AS02D and RTS,S/AS01E malaria candidate vaccines given according to different schedules in Ghanaian children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.041

Five-year safety and immunogenicity of GlaxoSmithKline's candidate malaria vaccine RTS,S/AS02 following administration to semi-immune adult men living in a malaria-endemic region of The Gambia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.041

Immunity and immunological memory following smallpox vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.041

Long-lived antibody and B Cell memory responses to the human malaria parasites, Plasmodium falciparum and Plasmodium vivax

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.041

Insights into long-lasting protection induced by RTS,S/AS02A malaria vaccine: further results from a phase IIb trial in Mozambican children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.041

Opsonization by antigen-specific antibodies as a mechanism of protective immunity induced by Plasmodium falciparum circumsporozoite protein-based vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.041

10.1016/J.VACCINE.2011.03.041

7 January 2021

Identifiers

DOI

1 reference

7 February 2018

PubMed ID

21443960

1 reference

7 February 2018